Announcements Trials
Browse Landscape

Phase

Phase 2 70Phase 3 33Phase 1 31Phase 1/2 21Phase 2/3 8Phase 4 3Phase NA 2Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1Adenoviridae Infections 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 9Biopsy 8Nivolumab 7Radiotherapy 6Specimen Handling 5Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Temozolomide 3Rituximab 3Paclitaxel 3Leukapheresis 3Dexamethasone 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Surgical Procedures, Operative 2Positron-Emission Tomography 2Phantoms, Imaging 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Irinotecan 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × atezolizumab × 90 days × Clear all
NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡